Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA

Design, technologies, and future prospects for developing countries

Victor J. Drew, Lassina Barro, Jerard Seghatchian, Thierry Burnouf

研究成果: 雜誌貢獻回顧型文獻

25 引文 (Scopus)

摘要

Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusiontransmitted infection. Without efficient donor screening/ viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol® Pathogen Reduction Technology, INTERCEPT®, and THERAFLEX®. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2nd-generation of the INTERCEPT® S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.
原文英語
頁(從 - 到)512-521
頁數10
期刊Blood Transfusion
15
發行號6
DOIs
出版狀態已發佈 - 2017

指紋

Viral DNA
Viral RNA
Developing Countries
Erythrocytes
Technology
Phase III Clinical Trials
Malaria
Infection
Tropical Climate
Blood Safety
Donor Selection
West Nile virus
Southeastern Asia
Ghana
Dengue Virus
Infectious Disease Transmission
Africa South of the Sahara
Syphilis
Ultraviolet Rays
Hepatitis B virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

引用此文

Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA : Design, technologies, and future prospects for developing countries. / Drew, Victor J.; Barro, Lassina; Seghatchian, Jerard; Burnouf, Thierry.

於: Blood Transfusion, 卷 15, 編號 6, 2017, p. 512-521.

研究成果: 雜誌貢獻回顧型文獻

@article{cd2f5fcd3a6044778b00a0d6b61cc0ae,
title = "Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: Design, technologies, and future prospects for developing countries",
abstract = "Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusiontransmitted infection. Without efficient donor screening/ viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol{\circledR} Pathogen Reduction Technology, INTERCEPT{\circledR}, and THERAFLEX{\circledR}. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2nd-generation of the INTERCEPT{\circledR} S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.",
keywords = "Blood, Inactivation, Pathogen, Red blood cell, Virus",
author = "Drew, {Victor J.} and Lassina Barro and Jerard Seghatchian and Thierry Burnouf",
year = "2017",
doi = "10.2450/2017.0344-16",
language = "English",
volume = "15",
pages = "512--521",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "SIMTI SrL",
number = "6",

}

TY - JOUR

T1 - Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA

T2 - Design, technologies, and future prospects for developing countries

AU - Drew, Victor J.

AU - Barro, Lassina

AU - Seghatchian, Jerard

AU - Burnouf, Thierry

PY - 2017

Y1 - 2017

N2 - Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusiontransmitted infection. Without efficient donor screening/ viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol® Pathogen Reduction Technology, INTERCEPT®, and THERAFLEX®. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2nd-generation of the INTERCEPT® S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.

AB - Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusiontransmitted infection. Without efficient donor screening/ viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol® Pathogen Reduction Technology, INTERCEPT®, and THERAFLEX®. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2nd-generation of the INTERCEPT® S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.

KW - Blood

KW - Inactivation

KW - Pathogen

KW - Red blood cell

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=85031943518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031943518&partnerID=8YFLogxK

U2 - 10.2450/2017.0344-16

DO - 10.2450/2017.0344-16

M3 - Review article

VL - 15

SP - 512

EP - 521

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 6

ER -